Skip to main content

Advertisement

Table 1 Patient characteristics including treatment and pathological parameters

From: Impact of Docetaxel on blood-brain barrier function and formation of breast cancer brain metastases

  BoM/ nBM (N) BM (N)
patients 40 40
deceased 14 14
Taxane (#) 30 38
 DTX 9 15
 Paclitaxel 17 14
 both 4 9
mean follow-up (##)
 days 2492.95 2545.15
 years 6.83 6.97
 age primary diagnosis (##) years 55.6 52.4
neoadjuvant therapy (#)
 yes 7 4
 no 29 29
 u 4 7
T (#)
 T1 9 7
 T2 15 13
 T3 5 7
 T4 6 7
 Tx 1 1
 Tis 0 1
 u 4 4
N (#)
 N0 10 16
 N1 13 11
 N2 5 4
 N3 8 5
 u 4 4
M (#)
 M0 17 23
 M1 15 8
 Mx 1 1
 u 7 8
grading (#) *
 G1 4 0
 G2 14 16
 G3 9 17
 u 13 7
ER (#) ***
 + 33 17
 - 5 19
 u 2 4
PR (#) *
 + 26 15
 - 12 20
 u 2 5
HER2/neu (#) *
 + 13 12
 - 24 21
 u 3 7
triple negative (#) *
 yes 3 9
 no 34 27
 u 3 4
intrinsic subtype (#) ***
 luminal 34 19
 basal-like 3 9
 Erb-B2 overexpression 0 8
 u 3 4
  1. BoM bone metastasis, nBM no brain metastasis, BM brain metastasis, u unknown. Statistical analysis was conducted using contingency analysis with likelihood-ratio/ Pearson test (#) or analysis of variance using one-way ANOVA (##). Significant differences are depicted as followed: * p<0.05; ** p<0.01; *** p<0.001